Contingent Consideration - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands				2 Months Ended		9 Months Ended
	Jun. 10, 2022	Nov. 19, 2020	Jul. 12, 2019	Jun. 10, 2022	Nov. 19, 2020	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Common stock issued related to contingent consideration liability						$ 6,176
Estimated future contingent consideration							$ 6,950	$ 6,090	$ 5,390
Change in value of contingent consideration for acquired in-process research and development						86	$ 1,560
Clinical Trial Notification [Member]
Business Acquisition [Line Items]
Common stock issued related to contingent consideration liability		$ 13,600
Shares issued for contingent milestone payment		1,694,906
Period for submission of clinical trial notification		60 days
Submission date of clinical trial notification		Oct. 29, 2020
Clinical Trial Notification [Member] | Regulatory Milestones [Member]
Business Acquisition [Line Items]
Change in value of contingent consideration for acquired in-process research and development					$ 5,400
Spitfire Pharma, Inc. [Member]
Business Acquisition [Line Items]
Agreement date			Jul. 08, 2019
Unregistered shares of common stock			1,887,250
Up-front consideration			$ 5,000
Spitfire Pharma, Inc. [Member] | Investigational New Drug Application Milestone [Member]
Business Acquisition [Line Items]
Estimated future contingent consideration			$ 5,000
Estimated future contingent consideration term			60 days
Number of consecutive trading days			20 days
Consideration amount			$ 2.95
Spitfire Pharma, Inc. [Member] | Investigational New Drug Application and Regulatory Milestones [Member]
Business Acquisition [Line Items]
Estimated future contingent consideration			$ 3,000
Estimated future contingent consideration term			60 days
Number of consecutive trading days			20 days
Consideration amount			$ 3.54
Spitfire Pharma, Inc. [Member] | Sales Milestones [Member]
Business Acquisition [Line Items]
Estimated future contingent consideration			$ 80,000
License agreement term			10 years
Spitfire Pharma, Inc. [Member] | Regulatory Milestones [Member]
Business Acquisition [Line Items]
Contingent consideration, percentage of shares released after three months			50.00%
Contingent consideration, percentage of shares released after six months			50.00%
Spitfire Pharma, Inc. [Member] | Phase Two Milestone [Member]
Business Acquisition [Line Items]
Common stock issued related to contingent consideration liability	$ 7,200
Estimated future contingent consideration						$ 0
Consideration amount	$ 8.55			$ 8.55
Shares issued for contingent milestone payment	847,444
Change in value of contingent consideration for acquired in-process research and development				$ 1,900
Spitfire Pharma, Inc. [Member] | Clinical Trial Notification [Member]
Business Acquisition [Line Items]
Consideration amount		$ 9.57			$ 9.57
Spitfire Pharma, Inc. [Member] | Common Stock [Member] | Maximum [Member]
Business Acquisition [Line Items]
Estimated future contingent consideration			$ 88,000